Due to the previously observed effects of enzalutamide on apoptotic gene expression [29], however, we chose to also examine apoptotic gene expression in enzalutamide-treated MDA MB 231 (ER-AR-) cells, as these cells represented the cancer subtype with the most unmet clinical need. The gene discussed is AR; the disease is cancer.